This book focuses on some of the new clinical and biological insights related to HIV-associated metabolic and cardiovascular complications in the HAART era. The introduction of highly active antiretroviral therapy (HAART) has altered cardiovascular manifestations in HIV. On the one hand, HAART has significantly improved the quality of life of HIV-infected patients. On the other hand, the early data have raised some concerns, creating an intriguing clinical scenery.